Browse by author
Lookup NU author(s): Dr Christoph OingORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2022, The Author(s). High-dose chemotherapy (HD-Cx) in refractory germ cell cancer (GCC) is effective but limited data are available concerning the optimal approach for stem cell mobilization (SCM) in these patients. In this analysis 102 patients undergoing SCM during first (n = 25) or subsequent treatment lines (n = 77) were analyzed. Subcutaneous injections of granulocyte colony-stimulating factor (G-CSF) were given once daily (group 1) in 52 patients (51%), twice daily (group 2) in 39 patients (38%) or one injection Pegylated-G-CSF (PegG-CSF) (group 3) in eleven patients (11%) after one cycle of mobilization chemotherapy. Plerixafor was administered 13 times in group 1, seven times in group 2 and once in group 3. Overall, 77 (75%) patients achieved successful SCM defined as ≥8*106 CD34+ cells/kg body weight for three consecutive HD-Cx plus one backup dose. In group 1, 40 of 52 patients (77%) achieved successful SCM with a median of 11 G-CSF injections, in group 2, 27 of 39 patients (69%) with a median of 14 G-CSF injections and in group 3, 10 of 11 patients (91%) with one injection of PegG-CSF. SCM was more successful if conducted during first-line chemotherapy (p = 0.016) and associated with a beneficial outcome concerning overall survival (p = 0.02) if performed satisfactorily.
Author(s): Madanchi R, Engel NW, Alsdorf W, Oing C, Frenzel C, Paulsen F-O, Bokemeyer C, Seidel C
Publication type: Article
Publication status: Published
Journal: Bone Marrow Transplantation
Year: 2022
Volume: 57
Issue: 5
Pages: 729-733
Print publication date: 01/05/2022
Online publication date: 21/02/2022
Acceptance date: 08/02/2022
Date deposited: 24/07/2024
ISSN (print): 0268-3369
ISSN (electronic): 1476-5365
Publisher: Springer Nature
URL: https://doi.org/10.1038/s41409-022-01614-9
DOI: 10.1038/s41409-022-01614-9
PubMed id: 35190673
Altmetrics provided by Altmetric
